Speakers
Hozefa Bandukwala
Vice President, Platform Innovation and Biology
Sigilon
Day One
Wednesday – January 27, 2021
5:10 pm | Shielded Living Therapeutics (SLTx): A novel allogeneic cell therapy platform for induction of antigen-specific immune tolerance & restoration of immune homeostasis.
Saso Cermerski
VP & Head of Discovery & Translational Immunology
Cue Biopharma
Day One
Wednesday – January 27, 2021
4:40 pm | Directly Targeting Autoantigen-Specific T-Cells
Ciaran P. Kelly
Professor of Medicine/Chief/Director/Medical Director
Harvard Medical School/Herman L. Blumgart Internal Medicine Firm/Gastroenterology Fellowship Training/Celiac Center
Day One
Wednesday – January 27, 2021
10:00 am | Success Story: Gliadin-Encapsulating Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease – Results of A Phase 1/ 2 Placebo-Controlled Clinical Trial
Richard Boismenu
Chief Scientific Officer
IgGenix
Day Two
Thursday – January 28, 2021
3:30 pm | Panel: Developing Precision Immune Tolerance Therapeutics
Kei Kishimoto
Chief Scientific Officer
Selecta Biosciences
Day One
Wednesday – January 27, 2021
11:40 am | Challenges and Opportunities for Immune Tolerance Induction in AAV Gene Therapy
Antoon Van Oosterhout
Chief Scientific Officer VP R&D
Imcyse
Day One
Wednesday – January 27, 2021
2:10 pm | Induction of cytolytic phenotype in human and mouse CD4+ T-cells by MOG-derived Imotopes™ and validation of the immunosuppressive capacity in mouse models of Multiple Sclerosis
Simi Ahmed
Director of Research & Lead of the Immune Therapies Program
JDRF
Day One
Wednesday – January 27, 2021
9:10 am | Panel: What Progress Has There Been in Achieving Antigen Specific Therapeutics
Shinu John
Associate Director, Immune Tolerance
SQZ Biotechnologies
Day One
Wednesday – January 27, 2021
4:10 pm | Cell Squeezing RBCs to Create Therapy for Inducing Antigen- Specific Tolerance
Jean Van Rampelbergh
VP Clinical & Regulatory
Imcyse
Day Two
Thursday – January 28, 2021
11:20 am | Imotope™ IMCY-0098 for the Treatment of Type 1 Diabetes: Lessons From Phase 1 Study for Phase 2 IMPACT trial
Randolph Noelle
Professor, Dartmouth Medical School; Co- Founder & Vice Chair
ImmuNext
Day Two
Thursday – January 28, 2021
3:00 pm | Magnifying Antigen-Specific Tolerance
Jose Carballido
Executive Director (Translational Medicine/ Preclinical Safety)
Novartis
Day One
Wednesday – January 27, 2021
9:10 am | Panel: What Progress Has There Been in Achieving Antigen Specific Therapeutics
Charlotte Fribert
Chief Executive Officer
Toleranzia AB
Day Two
Thursday – January 28, 2021
1:00 pm | TOL2 and TOL3: Antigen Specific Tolerogenic Therapies for the Treatment of Myasthenia Gravis and ANCA vasculitis
David Wraith
Founder & Chief Scientific Officer – Apitope; Director, Institute of Immunology & Immunotherapy
University of Birmingham
Day One
Wednesday – January 27, 2021
12:10 pm | Developing Robust Data to Valid MoA & Demonstrate Clinical Proof of Concept
9:10 am | Panel: What Progress Has There Been in Achieving Antigen Specific Therapeutics
Gerald Rea
Chief Executive Officer
Toralgen
Day Two
Thursday – January 28, 2021
2:30 pm | Treg-Enhancing Approaches to Drive Tolerance Induction in the Clinic
Brendan Classon
Vice President Research & Development
Parvus Therapeutics
Day One
Wednesday – January 27, 2021
2:40 pm | Developing Biomarker Assays that Can Inform Both Target Engagement & Pharmacodynamic Effects
AbdulSalam Shaaban
Senior Director
Rubius Therapeutics
Day Two
Thursday – January 28, 2021
8:45 am | Opening remarks from co-chair
Li Zhang
Assistant Professor Medicine-Endocrinology
Baylor College of Medicine
Day Two
Thursday – January 28, 2021
9:20 am | Monoclonal Antibodies Specific for Multiple Novel Targets to Suppress Type 1 Diabetes (t1d).
Marius Albulescu
Global Clinical Program Lead
AstraZeneca
Day One
Wednesday – January 27, 2021
3:40 pm | Biomarker-Driven Trial Design and Patient Stratification for Clinical Trials
Dr Bruce Mazer
Associate Scientific Director, Strategy
Canadian Covid-19 Immunity Task Force
Day One
Wednesday – January 27, 2021
1:40 pm | Developing Suitable Preclinical Models to Enable Successful Clinical Translation
Matthias Von Herrath
Vice President & Senior Medical Officer, Global Chief Medical Office
Novo Nordisk
Day Two
Thursday – January 28, 2021
11:50 am | Can Antigen Specific Immune Therapy Control Tissue Resident Effector T cells in Human Type 1 Diabetes?
Ranjeny Thomas
Professor of Rheumatology
University of Queensland, Translational Research Institute
Day Two
Thursday – January 28, 2021
1:30 pm | Delivery of Autoantigenic peptides/proteins to APCs Using Nanoparticle Vehicles; Challenges In the Pursuit of Immune Tolerance in Progressive Autoimmune Diseases
Andreas Lutterotti
Head of Experimental Therapies Research
University Hospital Zurich
Day One
Wednesday – January 27, 2021
10:30 am | Challenges in Defining & Measuring Immunological Tolerance in the Long Term
Stuart Mannering
ASI Visiting Speaker Program Coordinator, Head, Human T-cell Laboratory Immunology and Diabetes Unit
St. Vincent’s Institute of Medical Research
Vincent Dioszeghy
Researcher
DBV Technologies
Day Two
Thursday – January 28, 2021
9:50 am | Combination therapy with Tregitope and Cashew Improves & Accelerates Therapeutic Effects of Epicutaneous Immunotherapy in a Robust Mouse Model of Cashew Allergy
Mojca Skoberne
Senior Vice President & Head of Immunology & Early Development
Repertoire Immune Medicines
Day Two
Thursday – January 28, 2021
8:50 am | Overcoming Challenges of Target Discovery in Autoimmune Diseases
AbdulSalam Shaabam
Senior Director
Rubius Therapeutics